Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
J Ethnopharmacol. 2024 Jan 10;318(Pt B):117001. doi: 10.1016/j.jep.2023.117001. Epub 2023 Aug 6.
Fuzheng Huayu recipe (FZHY) is a commonly used Traditional Chinese Medicine formula for treating liver fibrosis in clinical settings. Despite its widespread use, the specific curative effects and underlying pharmacological mechanisms of FZHY in treating liver fibrosis are not yet fully understood.
This study aims to investigate the antifibrotic mechanism of FZHY treatment by exploring its effects on the activation of NOD-like receptor protein 3 (NLRP3) inflammasome in macrophages.
In order to investigate the impact of FZHY on the activation and priming of NLRP3 inflammasome in clinical trials and animal experiments using immunohistochemistry and Western blotting. Twenty-four C57BL/6 mice were used to induce liver fibrosis by feeding a diet that contained 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC). To study inflammasome function, Lipopolysaccharide (LPS)/adenine triphosphate (ATP) induced NLRP3 inflammasome activation was induced in bone marrow-derived macrophages (BMDMs) isolated from wild mice. The effects of macrophage NLRP3 inflammasome activation on the function of hepatic stellate cells (HSCs) were explored by treating primary HSCs with preconditioned media from BMDMs culture.
FZHY treatment resulted in the downregulation of NLRP3 protein expression and inhibition of its priming and activation in both human fibrotic livers and DDC-induced liver fibrosis. Furthermore, FZHY was observed to block the activation of the NLRP3 inflammasome pathway, which can lead to excessive inflammatory cytokine release in supernatants and cell lysates in response to LPS and ATP. Lastly, treatment with FZHY was able to inhibit the activation of HSCs induced by supernatants from macrophages.
FZHY has been shown to potentially prevent NLRP3 inflammasome activation in macrophages which can result in the suppression of HSCs activation. Ultimately, these effects may lead to the improvement of liver fibrosis. The ability of FZHY to act on this novel mechanism represents an important aspect of its therapeutic potential for liver fibrosis.
扶正化瘀方(FZHY)是一种常用于临床治疗肝纤维化的中药方剂。尽管它被广泛应用,但 FZHY 治疗肝纤维化的确切疗效和潜在的药理机制尚未完全阐明。
本研究旨在通过探讨 FZHY 对巨噬细胞中 NOD 样受体蛋白 3(NLRP3)炎性小体激活的影响,研究其抗纤维化的机制。
为了在临床试验和动物实验中研究 FZHY 对 NLRP3 炎性小体激活和启动的影响,采用免疫组织化学和 Western blot 法。用 3,5-二乙氧基羰基-1,4-二氢吡啶(DDC)喂养的饮食诱导 24 只 C57BL/6 小鼠产生肝纤维化。为了研究炎性小体的功能,用脂多糖(LPS)/三磷酸腺苷(ATP)诱导从野生型小鼠分离的骨髓源性巨噬细胞(BMDM)中 NLRP3 炎性小体的激活。用预处理的 BMDM 培养上清液处理原代肝星状细胞(HSCs),探讨巨噬细胞 NLRP3 炎性小体激活对 HSCs 功能的影响。
FZHY 治疗可下调人纤维化肝脏和 DDC 诱导的肝纤维化中 NLRP3 蛋白的表达,并抑制其启动和激活。此外,观察到 FZHY 阻断 NLRP3 炎性小体途径的激活,导致 LPS 和 ATP 刺激后上清液和细胞裂解物中过度炎症细胞因子释放。最后,FZHY 治疗可抑制巨噬细胞上清液诱导的 HSCs 的激活。
FZHY 可抑制巨噬细胞中 NLRP3 炎性小体的激活,从而抑制 HSCs 的激活。最终,这些作用可能导致肝纤维化的改善。FZHY 作用于这一新型机制的能力代表了其治疗肝纤维化的潜在治疗潜力的一个重要方面。